5 Result(s)
within
Article
Riccardo Masetti
English
Biomedicine, general
-
Article
Open AccessSafety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2− Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study
Ribociclib plus letrozole demonstrated manageable safety and efficacy profiles in hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2−) advanced breast cancer (ABC) in the ...
-
Article
Publisher Correction: Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes
-
Article
Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes
Germline SAMD9 and SAMD9L mutations (SAMD9/9Lmut) predispose to myelodysplastic syndromes (MDS) with propensity for somatic rescue. In this study, we investigated a clinically annotated pediatric MDS cohort (n = ...
-
Article
Open AccessPONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
Clinicopathological prognostic features have limited value to identify with precision newly diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer (BC), who would benefit from chem...
-
Article
Open AccessNeoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
This randomised, double-blind study compared pharmacokinetics, efficacy, safety and immunogenicity of PF-05280014 (potential trastuzumab biosimilar) and trastuzumab reference product (Herceptin) sourced from t...
